Bone loss in inflammatory Bowel disease: our multicentric study

Patients with inflammatory bowel disease are at increased risk of developing disorder in bone and mineral metabolism The study was aimed to determine if inflammatory bowel disease (IBD) is a risk factor for osteoporosis in 103 adult patients. We included 103 IBD patients, 67 patients with Crohn's disease (CD) and 36 with ulcerative colitis (UC). Bone mineral density was measured by dual-energy X-ray absorptiometry. We used T score to express bone loss (osteopenia: -2.5 SD 2 years) and active disease would be risk factors of bone mineral loss in IBD

Intestinal microbiota mutualism and gastrointestinal diseases

The purpose of this work is to investigate the link between an altered intestinal mcro-biota or dysbiosis and chronic inflammatory disorders, in particular inflammatory bowel disease (IBD). Along with probiotics, faecal microbiota transplantation (FMT) opts to be a promising therapeutic treatment for restoring the bacterial homeostasis of the hu-man intestine and reducing the risk of colorectal carcinogenesis. Microbiota is the com-plex microbial flora that resides in the gut establishing a mutually beneficial relation-ship. Alteration of the microbiota’s composition, termed as dysbiosis, may lead to pathological conditions. Treatment with probiotics can restore the normal commensal flora in IBD. Intestinal microbiota affects the circadian rhythm which in turn regulates the expression of different genes in GALT (gut associated lymphoid tissue) playing a role in the prevention of inflammation and colorectal cancer (CRC) progression. This article highlights the involvement of different microbial strains in the pathogenesis of dysbiosis and in the creation of a carcinogenic milieu caused by an altered stimulation of the immune system. Therapies targeting the equilibrium of the microbiota to switch off chronic inflammation and prevent the progression to CRC seem to be a promising therapeutic tool for a variety of inflammation-associated diseases

INFLAMMATORY BOWEL DISEASE AND EXTRAINTESTINAL MANIFESTATIONS

Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, are chronic and recurrent inflammatory diseases. Although the typical symptoms are localized in the gastrointestinal tract, there are also extraintestinal manifestations (EIMs) associated with IBD, probably caused by immune reactions secondary to the pathology of origin. Anybody can be affected by EIMs, which can be dermatological, pulmonary, ocular, musculoskeletal, hepatobiliary and neurological, et al. This represents a therapeutic challenge for clinicians, who must first establish a diagnostic and then a multidisciplinary therapeutic path, in order to guarantee an optimal quality of life for the patient

Bone loss in inflammatory Bowel disease: our multicentric study

Patients with inflammatory bowel disease are at increased risk of developing disorder in bone and mineral metabolism The study was aimed to determine if inflammatory bowel disease (IBD) is a risk factor for osteoporosis in 103 adult patients. We included 103 IBD patients, 67 patients with Crohn's disease (CD) and 36 with ulcerative colitis (UC). Bone mineral density was measured by dual-energy X-ray absorptiometry. We used T score to express bone loss (osteopenia: -2.5 SD 2 years) and active disease would be risk factors of bone mineral loss in IBD

Association Between Helycobacter Pylori Infection and Pathological Oral Manifestations

Data from the literature are controversial regarding the presence of Helicobacter pylori (H. pylori) in dental plaque and its association with gastric infection. One of the possible mechanisms suggested for re-infection is the recolonization with H. pylori from dental plaque. The purpose of this review was to determine whether dental plaque, poor oral hygiene, and periodontal disease were risk factors for H. pylori infection

A MIXTURE OF VEGETABLE EXTRACTS (CHAMOMILLE, PASSIONFLOWER, CARAWAY, FENNEL), AND ENZYMES (BETA-GALACTOSIDASE) FOR IRRITABLE BOWEL SYNDROME (ibs): AN OBSERVATIONAL STUDY ("BIOVES")

Summary. Aims: Irritable bowel syndrome (IBS) is a functional intestinal disorder. This syndrome may creates psychological disorders in patients who are affected and severely limits daily activities and lifestyle. Methods: We investigated the effect of the natural product consisting of chamomile, fennel, caraway, passionflower and melissa (Spasmicol®), on IBS patients. For the study, 187 patients with IBS, enrolled by primary care doctors, were treated with Spasmicol® (Aristeia Farmaceutici s.r.l.), two tablets/daily, for 30 days. At the end of the study, patients were re-evaluated to analyse the effects of therapy. Results: After 30 days, patients showed a marked reduction of symptoms (abdominal pain, abdominal distention, stool habit changes). Conclusions: Due to to the combination of chamomile, fennel, caraway, melissa, passionflower and beta-galactosidase, the product Spasmicol® turned out to be remarkedly effective in treating IBS symptoms